NCT05668936 - A Thorough QTC Study to Assess the Effect of Cotadutide on Cardiac Repolarization in Healthy Participants | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 3, 2023

Primary Completion Date

March 10, 2023

Study Completion Date

March 10, 2023

Conditions

Non-alcoholic Steatohepatitis

Interventions

DRUG

Cotadutide

Participants will receive a subcutaneous injection of cotadutide.

DRUG

Cotadutide-placebo

Participants will receive a subcutaneous injection of cotadutide-placebo.

DRUG

Moxifloxacin

Participants will receive a single oral dose of Moxifloxacin film-coated tablet.

DRUG

Moxifloxacin-placebo

Participants will receive a single oral dose of Moxifloxacin-placebo film-coated tablet.

Trial Locations (1)

Research Site, Berlin